IDRA-21 AMPAkine supplementation for targeted health support.
Compounds that enhance AMPA glutamate receptor activity. This affects learning and memory at the fundamental synaptic level. Several are in pharmaceutical development.
Gray area. Not scheduled, but not approved for human consumption. Sold as a research chemical. Legal status varies by jurisdiction.
Different mechanism. Racetams have various effects on acetylcholine and glutamate. IDRA-21 specifically targets AMPA receptors. More targeted but less studied.
Click through to the studies bar for the evidence base.
See the dosing guide below.
Compare formats before buying.
Some ingredients build up over weeks. Others act fast.
The compound effect of consistent dosing.
Check the cautions section if you have a pre-existing condition.
Some ingredients you feel. Others just work in the background.
Unknown. Animal studies exist but human data is minimal. The mechanism (enhancing glutamate) carries theoretical excitotoxicity risk.
Pharmaceutical development is expensive. Some ampakines have progressed, but IDRA-21 was eclipsed by newer compounds with better profiles.
Almost no one. Only people who thoroughly understand the risks, have researched extensively, and accept experimental status. Not for casual nootropic users.
Most research uses 0.0g daily. Below 0.0g, you're probably wasting money. Above 0.1g, no extra benefit. The curve plateaus. Safe upper limit ~ 0.1g.
IDRA-21 AMPAkine has emerging evidence.
Synthetic compound, no natural sources
IDRA-21 AMPAkine interacts with other supplements and meds. The analyzer flags interactions, dose mismatches, and timing collisions across your whole list.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.